Today, BrainStorm Cell Therapeutics Inc. took the opportunity to announce that the company’s therapeutic treatment for neurodegenerative diseases displayed superior results to other current potential stem cell treatments in a recently conducted study.

The Israel Medical Association Journal published a scientific paper, authored by Ofer Sadan, Eldad Melamed and Daniel Offen from Tel Aviv University, showing the migratory capacity of Neurotrophic Factor Stem Cells (NTF-SC) in animal models of Parkinson’s and Huntington diseases. The study demonstrated that in a rat model for Parkinson’s disease, the efficacy of NTF-SC was superior in behavior, biochemical and histological indices to that of mesenchymal stem cells. The complete study and scientific paper are available on Brainstorm’s website at

Professor Daniel Offen, Brainstorm’s chief scientific advisor, commented, “The results of this study show that the NTF-SC based treatment is efficacious due to NTF secretion and the stem cell’s migratory capabilities. Since our novel technology is clinically compatible and safe, the study suggests that in the future, cell therapy based on the transplantation of NTF-SC derived from autologous human mesenchymal stem cells should become a preferable option in the treatment of neurodegenerative diseases.”

Brainstorm’s CEO, Rami Efrati, added, “This study demonstrates that Brainstorm’s approach in differentiating adult mesenchymal stem cells into NTF-SC, will provide the most effective approach for the treatment of neurodegenerative diseases via the use of stem cells. As we near clinical trials, the Company and its scientific team will continue to study how our technology and methodology can be further utilized with other neurodegenerative diseases.”